gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · CLNNHealthcarePharmaceuticals

Clene Inc. Common Stock (CLNN)

$4.10+8.75%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$4.10▼ 62.45% in range
Nov 4, 2025Low $3.10 · High $10.92Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Clene closed at $4.10 on Nov 4, up 8.75%, 65.8% below its 52-week closing high. Volume of 115.9K shares was 1.47× its 20-day average (above normal).

Split-adjusted performance: +5.9% over one month, -42.7% over six months, -65.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $90K, up 233.3% from a year earlier, with a net margin of -14915.6%.

Short interest was 424.9K shares at the Oct 15 settlement, down 51.8% from the prior report (4.6% of float, 4.5 days to cover).

Market cap$58.3M14.2M shares
Revenue · quarter$90.0K+233.3% YoY
Diluted EPS$-1.08—
P/E · TTM—P/S 295.8×
Net margin-14,915.6%Gross 60.0%
Dividend yieldNone
52-week range3.10 – 11.98−65.8% from high
Volume115.9K1.47× 20-day avg
Volatility · 60d77.9%Annualised
Short % of float4.6%4.5 days to cover
Net cash-$9.1MCash $9.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +1.7%1M +5.9%3M −23.2%6M −42.7%YTD −30.2%1Y −65.8%3Y −49.4%5Y −96.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum31
Revenue growth90
Net margin4
Value (low P/E)—
Size34

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short424.9K−51.8% vs prior
Days to cover4.5Settled Oct 15
% of float4.6%
Short vol. 10d38.5%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
CLNNClene$4.10+8.75%−42.7%+233.3%−14915.6%—$58.3M
NMADNomad Power Solutions$3.60+2.27%————$58.0MCompare
CTORCitius Oncology$0.5470−0.55%−39.8%—−597.4%—$57.9MCompare
RNXTRenovoRx$1.31+1.55%+47.2%+115.4%−320.2%—$59.1MCompare
XLOXilio Therapeutics$8.71+0.35%+10.3%+131.2%−34.1%—$57.3MCompare
VRCAVerrica Pharmaceuticals$3.46+5.02%−59.0%−53.8%−224.4%—$59.4MCompare
XBITXBiotech$1.95−2.01%−23.5%———$59.5MCompare
RNTXRein Therapeutics$0.6587−1.32%−43.7%———$56.8MCompare
HRTXHeron Therapeutics$0.2986+4.88%−77.2%+1.3%−14.6%—$56.7MCompare

News about Clene

All news →
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSGlobeNewswire Inc. · Oct 19, 2026▲ Positive

Quick answers

What does Clene do?
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases.
What is CLNN's market cap?
$58.28M, based on the Nov 4 close of $4.10.
Does Clene pay a dividend?
No regular cash dividend has been paid in the last year.
How much of CLNN is sold short?
424.9K shares, 4.6% of float, as of Oct 15, 2026.
What sector is CLNN in?
Healthcare, in the Pharmaceuticals industry.

About Clene

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

HQ: Salt Lake City, UT79 employeesListed Dec 31, 2020clene.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology